NEW YORK (
CHANGE IN RATINGS
upgraded at JP Morgan. Rating raised to Neutral from Underweight. Maintains $7.50 price target. Raises 2010 EPS estimates from $0.14 to $0.52.
Advanced Micro Devices
rated new Buy at ThinkEquity. Company is positioned well to benefit from the refresh cycle in computers and servers.
upgraded at Credit Suisse to Hold from Sell as BJ services acquisition is complete. Price target raised to $53 from $46. 2010 and 2011 EPS estimates increased to $2.05 and $3.00, respectively.
upgraded at Suntrust from Neutral to Buy. $26 price target. Company is posting better results, aided by an improving credit environment.
downgraded at FBR from Market Perform to Underperform. $13 price target. Enrollment growth could turn negative, given cohort default rates and concentration of Title IV funds.
downgraded at ThinkEquity from Buy to Hold. New analyst raised estimates, to reflect higher gross margins, but the stock appears fully valued.
downgraded at JP Morgan. Rating lowered to Neutral from Overweight. Price target lowered to $13 from $60. 2010 EPS estimates lowered to -$2.10 from -$2.41.
downgraded at Oppenheimer from Outperform to Perform. Company may have to raise more capital, following the FDA's request for further trials.
downgraded at Wells from Outperform to Market Perform. FDA response represents a potential 4-year delay in Esbriet.
downgraded at Goldman from Buy to Neutral. Company was also removed from the Conviction List, as the company lacks meaningful catalysts. $42 price target.
upgraded at ThinkEquity from Hold to Buy. New analyst believes that business activity will pick up in the second half of fiscal 2011.
downgraded at Baird from Outperform to Neutral. $29 price target. Company is seeing lower Nexavar sales.
numbers upped at Morgan Stanley through 2012. Company is seeing lower Nexavar sales and higher operating costs. Underweight rating and new $25 price target.
upgraded at Deutsche from Hold to Buy. $6 price target. Fundamentals are beginning to show signs of improvement.
( WXS) upgraded at Goldman from Neutral to Buy. $41 price target. Fleet demand should improve along with the macro environment.
STOCK COMMENTS / EPS CHANGES
estimates lowered at Morgan Stanley through 2012. Company has a tepid near-term outlook for ethanol and oilseed processing margins. Overweight rating and $33 price target.
estimates, target raised at FBR. Shares of ANN now seen reaching $28. Estimates also increased, to match the company's new guidance. Outperform rating.
estimates, target boosted at UBS. Shares of ATML now seen reaching 2011. Estimates also upped, given the company's operating leverage. Buy rating and new $6.75 price target.
price target raised at Citi to $7 from $6.25. Management can now focus on improving the business as opposed to the balance sheet. Maintain Hold rating.
( CEPH) estimates increased at UBS through 2011. Company is seeing higher sales and cut operating expenses. Buy rating and $80 price target.
numbers raised at Morgan Stanley. Shares of EMR now seen reaching $54. Estimates also increased, given higher overall orders. Equal-weight rating and new $54 price target.
estimates, target boosted at Morgan Stanley. Shares of FPL now seen reaching $52. Estimates also upped, given multiple potential avenues of growth. Equal-weight rating.
estimates increased at FBR through 2011. Company is buying back shares sooner than expected. Outperform rating and $44 price target.
target, estimates boosted at Citi. MA price target jumped to $265 from $250 on strong core spending trends. 2010 and 2011 EPS estimates raised to $13.75 and $16.58, respectively. Reiterate Hold.
numbers boosted at Goldman. Shares of MLM now seen reaching $110, according to Goldman Sachs. Estimates also upped, as aggregate volumes should recover faster, given stimulus spending. Buy rating.
numbers raised at UBS. Shares of MRO now seen reaching $33. Estimates also increased, given the company's new production guidance. Neutral rating.
estimates, target cut at FBR. MSTR estimates were lowered through 2011. Company is spending more on aggressive hiring. Market Perform rating and new $85 price target.
estimates cut at Morgan Stanley through 2012. Economic headwinds are hurting patient volumes. Equal-weight rating.
price target higher at Citi. OPEN price target lifted to $45 from $38 on strong 1Q10 results. 2010 and 2011 EPS estimates raised to 54 cents and 74 cents, respectively. Maintain Buy.
estimates lowered at UBS. TAP estimates were cut through 2011. Company is spending more, offsetting improving North American sales. Buy rating and $50 price target.
numbers boosted at FBR. Shares of TE now seen reaching $17. Estimates also upped, given higher earnings from the coal business. Market Perform rating.
estimates cut at UBS through 2011. Management said that the company is having trouble passing along higher liquid asphalt costs. Neutral rating and $62 price target.
target raised, estimates changed at Citi. WBMD price target improved to $56 from $49 on beat & in-line 1Q10 results. Reiterate Buy rating. 2010 EPS estimate lowered to 66 cents, 2011 increased to $1.15.
estimates lowered at Morgan Stanley through 2012. Company us seeing a higher share count. Equal-weight rating.
This article was written by a staff member of TheStreet.com.